ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 648

Are Choline Metabolites Associated with Inflammation in Psoriatic Arthritis?

Roxana Coras1,2, Arthur Kavanaugh2, Doquyen Huynh3, Mohit Jain2 and Monica Guma2, 1Medicine, Autonomous University of Barcelona, Barcelona, Spain, 2Medicine, University of California, San Diego, La Jolla, CA, 3Medicine, University of California, San Diego, San Diego, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: dietary supplements, metabolomics and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease affecting the joints and connective tissue and is associated with psoriasis of the skin and nails. In our daily clinical routine, patients often report changes in their disease activity with certain foods, despite the ongoing treatment. Choline metabolism has been recently strongly related to inflammation. Dietary intake of choline, through two circulating metabolites, trimethylamine (TMA), and trimethylamine N-oxide (TMAO), are mechanistically linked to cardiovascular inflammation. The objective of this study was to explore the link between choline metabolites and inflammation in PsA.

Methods: Patients with PsA, diagnosed based on the CASPAR criteria, were recruited from the Rheumatology Outpatient Clinic at the University of California, San Diego. A thorough clinical examination, including joint and skin disease evaluations, was conducted. Patients completed a health assessment questionnaire. DAS28, Clinical Disease Index (CDAI) and Simple Disease Index (SDAI) scores and body surface area (BSA) of psoriasis were calculated. Serum concentration of choline metabolites: choline, TMA, TMAO, and betaine were determined by Mass Spectrometry. Inflammatory biomarkers in serum were determined by ELISA. Statistical analysis included means, standard deviation, t-test and Pearson correlation.

Results: 38 patients (average age 47.45 years, standard deviation [SD] 10.29) were recruited. The mean (SDs) of DAS28PCR was 2.24 (1.29). 27 patients (71.05%) had active skin disease, with an average BSA of 4.73 (SD, 14.5). 23.68% of patients had enthesitis, 5.26% had dactylitis and 47.36% had nail involvement. 65.11% received biological therapy (46.42% of them in association with a synthetic disease modifying drug DMARD), 13.95% received sDMARD in monotherapy and 20.9% received symptomatic treatment. We found that TMAO, a choline metabolite, correlated with parameters of disease activity for both skin (BSA) and joint (DAS28, CDAI, SDAI) (Table 1). Choline, TMA and TMAO also correlated with inflammatory markers (Table 2). TMAO was higher in patients with active joint disease (CDAI>2.8) versus patients in remission (CDAI<2.8; p = 0.01) and in patients with higher severity of skin disease (BSA >5%) versus low severity (BSA <5%; p = 0.03).

Table 1. Correlation between choline metabolites and disease activity

Metabolite

DAS28CRP

CDAI

SDAI

BSA

Swollen joints count

Dactylitis

TMAO

0.341**

0.338**

0.377**

0.687***

0.428***

0.663***

* p<0.1, ** p<0.05, *** p<0.01

Table 2. Correlation between choline metabolism and inflammatory markers

Metabolite

SAA

CRP

IL6

TNF-RI

MMP1

MMP3

Leptin

Resistin

IL-8

Choline

0.286*

0.367**

0.643***

0.467***

TMA

0.315*

0.709***

0.573***

0.380**

TMAO

0.517***

0.709***

0.416**

0.330*

0.385**

Betaine

SAA-Serum amyloid A; CRP-C reactive protein; IL-Interleukin; TNF-RI-Soluble tumor necrosis alpha receptor type I; MMP-Metalloproteinase. * p<0.1, ** p<0.05, *** p<0.01

Conclusion: In our cohort, choline metabolism was associated with inflammation in PsA patients. Since diet is the main source of choline, modulating choline food intake might help to better control disease activity in these patients. Further studies are needed to explore the mechanistic links between choline and TMAO and inflammation.


Disclosure: R. Coras, None; A. Kavanaugh, None; D. Huynh, None; M. Jain, None; M. Guma, None.

To cite this abstract in AMA style:

Coras R, Kavanaugh A, Huynh D, Jain M, Guma M. Are Choline Metabolites Associated with Inflammation in Psoriatic Arthritis? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/are-choline-metabolites-associated-with-inflammation-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-choline-metabolites-associated-with-inflammation-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology